Using statins for the primary prevention of VTE may slightly reduce the incidence of VTE and all-cause mortality. However, this effect is likely too weak to be considered significant. Statin use may ...

A rare type of pulmonary hypertension (PH), CTEPH is caused by the formation of blood clots in the pulmonary arteries ...

Every day, countless individuals may experience symptoms linked to blood clots without realizing it. According to the Centers for Disease Control and Prevention (CDC), approximately 900,000 people in ...

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) recently awarded a $3.7 ...

A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...

For people with stroke, social factors such as race, neighborhood and insurance, may be linked to whether they receive treatment ... received clot-busting drugs and 5,951 people, or 4%, received ...

The data published in The Lancet is being heralded as a big breakthrough in the treatment of cervical cancer and uses readily available chemotherapy drugs, given to patients before they receive ...

For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months ...

Alectinib, also known as Alecensa, is recommended as an option for the treatment of stage 1B (tumours 4cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after surgery to completely ...

for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. "Novocure is committed to extending survival in ...

Item-level targeting was adequate given the nature of the target construct (i.e. a scale that taps into aspects of treatment satisfaction would be expected to result in a degree of skew to the ...